CO*RE 2024-2025 CURRICULUM ON PAIN MANAGEMENT

The CO*RE 2024-2025 curriculum, created by renowned pain management and addiction experts addresses pain pathophysiology, patient assessment, patient-centered treatment plans, non-pharmaceutical options, opioid management, patient education, and opioid use disorder.

This program meets many states’ requirements for pain education and is fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement (“Blueprint”), issued by the U.S. Food & Drug Administration. Additionally this education may be used to satisfy, in part, requirements of the MATE Act, as noted in SAMHSA Recommendations for Curricular Elements in Substance Use Disorder.

This education can be delivered at your next conference or meeting. Please email JerriDavis@core-rems.org for additional information. You can select a course option that fits the needs of your audience. We offer two types of curriculum for live or online education, and an online podcast.

CO*RE Didactic Curriculum
Our didactic learning session is designed to provide a comprehensive and structured approach to pain management education. This session meticulously follows the FDA Blueprint, ensuring that participants receive the most up-to-date and evidence-based knowledge.

CO*RE Case-Based Curriculum
Our case-based session delivers a real-world educational experience through a series of cases and supporting content mapped to the FDA Blueprint. This allows faculty to teach application of concepts, fostering an engaging approach to pain management education.

CO*RE Podcast Developed by ASAM
This series features three 45-minute podcasts aimed at empowering clinicians to manage pain confidently. The series also follows the FDA Blueprint, covering patient assessment, treatment plan creation, therapy initiation, modification, discontinuation, and patient counseling.

RESULTS

Since 2013, CO*RE has delivered high-quality, REMs-compliant education to more than 515,000 clinicians via more than 800+ CE/CME activities (through October 2024). Our in-person and online programs are designed to ensure consistency, effectiveness, and real-world applicability.

CO*RE uses a Common Outcomes Framework to align the FDA Blueprint with our learning objectives, content, and assessment questions. This standardized approach enhances course consistency and allows for more robust data analysis on educational impact.

We leverage a custom-built outcomes dashboard to analyze data, identify trends, and address emerging gaps in clinical practice. Key insights from our 2024 Outcomes Report include:

  • 55 accredited activities delivered in 2023-24 and reached 18,269 clinicians across all U.S. states. Darker shading on map indicates a higher number of completers.
  • 80% of post-activity respondents indicated they intend to make changes in their practice as a direct result of CO*RE education.
  • 70% of respondents to a follow-up outcomes survey confirmed they had made at least one improvement in their practice based on what they learned.
  • CO*RE-educated clinicians manage an estimated 1,000,000 patients per month presenting with pain, demonstrating the far-reaching impact of our education.

Summary chart of outcomes by content domain:

TESTIMONIALS

Was presented in a thorough and concise manner. The speaker clearly understood the topic well. Better than other similar courses I have taken elsewhere. Thank you!

This CE covered new information for me, I’m glad to get the web address for the Pain Assessment Tool.  I plan on using this information more with my patients.

Greatly appreciated this course.  Concise, timely, and rich with recommendations.

This was a wonderful overview with practical advice I can apply to my practice.

The podcast setting was a great way to engage and provide relevant information!  Thoroughly enjoyed the change from usual PowerPoints.

This was an excellent presentation with detaile dinformation, and went into more depth than other courses I have taken.

FUNDER INFORMATION

This educational activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies (RPC). This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration. Click here for more information about the Opioid Analgesics REMS.